Mersana Therapeutics (MRSN)
(Real Time Quote from BATS)
$3.16 USD
0.00 (0.00%)
Updated Apr 30, 2024 03:58 PM ET
After-Market: $3.18 +0.02 (0.63%) 4:16 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Mersana Therapeutics, Inc. [MRSN]
Reports for Purchase
Showing records 61 - 80 ( 197 total )
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
XMT-2056 Preclinical Data Presented and Target Disclosed at NCI-AACR-EORTC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expansion Study Update Confirms Prior Data, Supports UPLIFT Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Innovative Platforms Could Offer an Advantage in the ADC Market; Initiate Buy with $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Can UpRi Put the Bling back into Platinum Therapy
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2021 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D